These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 7531353)

  • 1. Survey on the pharmacodynamics of the new antipsychotic risperidone.
    Megens AA; Awouters FH; Schotte A; Meert TF; Dugovic C; Niemegeers CJ; Leysen JE
    Psychopharmacology (Berl); 1994 Feb; 114(1):9-23. PubMed ID: 7531353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical profile of risperidone, a new antipsychotic.
    Leysen JE; Gommeren W; Eens A; de Chaffoy de Courcelles D; Stoof JC; Janssen PA
    J Pharmacol Exp Ther; 1988 Nov; 247(2):661-70. PubMed ID: 2460616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.
    Janssen PA; Niemegeers CJ; Awouters F; Schellekens KH; Megens AA; Meert TF
    J Pharmacol Exp Ther; 1988 Feb; 244(2):685-93. PubMed ID: 2450200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography.
    Schotte A; Janssen PF; Megens AA; Leysen JE
    Brain Res; 1993 Dec; 631(2):191-202. PubMed ID: 7510574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.
    Leysen JE; Janssen PM; Megens AA; Schotte A
    J Clin Psychiatry; 1994 May; 55 Suppl():5-12. PubMed ID: 7520908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors.
    He H; Richardson JS
    Int Clin Psychopharmacol; 1995 Mar; 10(1):19-30. PubMed ID: 7542676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone.
    Leysen JE; Janssen PM; Gommeren W; Wynants J; Pauwels PJ; Janssen PA
    Mol Pharmacol; 1992 Mar; 41(3):494-508. PubMed ID: 1372084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is it possible to predict the clinical effects of neuroleptics from animal data? Part V: From haloperidol and pipamperone to risperidone.
    Janssen PA; Awouters FH
    Arzneimittelforschung; 1994 Mar; 44(3):269-77. PubMed ID: 7514873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598).
    Megens AA; Awouters FH; Meert TF; Schellekens KH; Niemegeers CJ; Janssen PA
    J Pharmacol Exp Ther; 1992 Jan; 260(1):146-59. PubMed ID: 1370538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors.
    Leysen JE; Janssen PM; Schotte A; Luyten WH; Megens AA
    Psychopharmacology (Berl); 1993; 112(1 Suppl):S40-54. PubMed ID: 7530377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Serotonin antagonism involved in the antipsychotic effect. Confirmation with ritanserine and risperidone].
    Niemegeers CJ; Awouters F; Janssen PA
    Encephale; 1990; 16(2):147-51. PubMed ID: 1693560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone.
    Nyberg S; Farde L; Eriksson L; Halldin C; Eriksson B
    Psychopharmacology (Berl); 1993; 110(3):265-72. PubMed ID: 7530376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of alcohol preference in rats induced by risperidone, a serotonin 5-HT2 and dopamine D2 receptor antagonist.
    Panocka I; Pompei P; Massi M
    Brain Res Bull; 1993; 31(5):595-9. PubMed ID: 7684315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional interaction between serotonin-S2 and dopamine-D2 neurotransmission as revealed by selective antagonism of hyper-reactivity to tryptamine and apomorphine.
    Awouters F; Niemegeers CJ; Megens AA; Janssen PA
    J Pharmacol Exp Ther; 1990 Sep; 254(3):945-51. PubMed ID: 1697623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat.
    van Beijsterveldt LE; Geerts RJ; Leysen JE; Megens AA; Van den Eynde HM; Meuldermans WE; Heykants JJ
    Psychopharmacology (Berl); 1994 Feb; 114(1):53-62. PubMed ID: 7531352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo dopamine-D2 and serotonin-5-HT2 receptor binding study of risperidone and haloperidol.
    Sumiyoshi T; Kido H; Sakamoto H; Urasaki K; Suzuki K; Yamaguchi N; Mori H; Shiba K; Yokogawa K
    Pharmacol Biochem Behav; 1994 Mar; 47(3):553-7. PubMed ID: 7516078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of clozapine and risperidone on 5-HT2 and D2-dopamine receptor binding in the post-mortem human brain. An autoradiographic study.
    Hall H; Halldin C; Nyberg S; Farde L; Sedvall G
    Eur Neuropsychopharmacol; 1995 Mar; 5(1):19-25. PubMed ID: 7542051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risperidone.
    Cohen LJ
    Pharmacotherapy; 1994; 14(3):253-65. PubMed ID: 7524043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
    Gardell LR; Vanover KE; Pounds L; Johnson RW; Barido R; Anderson GT; Veinbergs I; Dyssegaard A; Brunmark P; Tabatabaei A; Davis RE; Brann MR; Hacksell U; Bonhaus DW
    J Pharmacol Exp Ther; 2007 Aug; 322(2):862-70. PubMed ID: 17519387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulation by risperidone of rat prolactin secretion in vivo and in cultured pituitary cells in vitro.
    Bowden CR; Voina SJ; Woestenborghs R; De Coster R; Heykants J
    J Pharmacol Exp Ther; 1992 Aug; 262(2):699-706. PubMed ID: 1380082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.